Histamine News and Research

RSS

Histamine is a biogenic amine chemical involved in local immune responses as well as regulating physiological function in the gut and acting as a neurotransmitter.

Migraine prevention guidelines released

The latest migraine prevention guidelines will be presented at the American Academy of Neurology's annual meeting in New Orleans and published simultaneously in the journal Neurology.

24 Apr 2012

Risk of botulism at California fish processing company

The U.S. Food and Drug Administration, in a complaint filed by the Department of Justice, is seeking to stop the processing and distribution of fish products at a California company because of a risk of botulism and other food hazards.

30 Mar 2012

Gedeon Richter and Forest Labs' cariprazine Phase III trials on schizophrenia meet primary endpoint

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for the treatment of acute exacerbation of schizophrenia.

28 Feb 2012

DC-SIGN molecule appears to play a role in fighting allergy

Scientists at The University of Nottingham have discovered a new molecule that could offer the hope of new treatments for people allergic to the house dust mite.

15 Feb 2012

Acid reducing drugs could raise risk of C. diff diarrhea

U.S. health regulators, the Food and Drugs Administration (FDA), have announced that ulcer drugs such as AstraZeneca Plc's blockbuster Nexium could increase the risk of Clostridium difficile-associated diarrhea (CDAD).

9 Feb 2012

Certain strains of P. aeruginosa cause WBCs to produce high levels of histamine

Could some cases of asthma actually be caused by an allergic reaction to a common environmental bacteria? New research findings published in the Journal of Leukocyte Biology suggests that this idea may not be as far-fetched as it seems. In a research report appearing in the February 2012 print issue, researchers show a link between common environmental bacteria and airway inflammation.

1 Feb 2012

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Oxygen Biotherapeutics, Inc. has announced that enrollment for the company’s first dermatological study will begin later this month at St. John’s Medical College Hospital in Bangalore, India. The company received formal approval from the hospital’s Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne.

9 Jan 2012

HRF inhibitors may provide new therapeutic avenue for treatment of asthma and allergies

La Jolla Institute for Allergy & Immunology scientists have identified the histamine releasing factor (HRF) molecule as a promising target for developing new treatments for a number of allergic reactions including asthma.

3 Dec 2011

Experts share latest buzz on allergies to alcohol and tobacco

While the health benefits of drinking wine in moderation continue to make news, for some with allergies even a glass a day may be difficult to swallow. At the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Nov. 3-8, allergists share the latest buzz on allergies to alcohol and tobacco.

7 Nov 2011

Frozen ground tuna recalled by Osamu Corporation

Osamu Corporation of Gardena, CA is recalling up to 1,800 cases, lot# 7013, of frozen ground tuna because the FDA found decomposition in several samples of the product and also found elevated histamine levels in samples taken from one retail location.

14 Oct 2011

Aspirin desensitization procedure can benefit patients with sinusitis, asthma and AERD

Beth Moore can now keep up with her children. The suburban Philadelphia mother of two had suffered from allergies and chronic sinusitis since her teens. With age her symptoms became more severe, turning into bronchitis and eventually asthma, diminishing her ability to breathe and sapping her of her energy. The only complete relief came from aspirin; and the aspirin desensitization that allowed her to overcome her aspirin allergy and end her decades-long battle with sinusitis.

11 Oct 2011

Researchers identify gene responsible for aggressive, bold behavior in zebrafish

A gene responsible for aggressive and bold behavior has been identified in zebrafish by a team from CNRS/Laboratoire Neurobiologie et Développement.

7 Oct 2011

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Pfizer Inc. today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis, a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.

1 Oct 2011

Methylphenidate drug may induce arousal from general anesthesia

Administration of the commonly used stimulant drug methylphenidate (Ritalin) was able to speed recovery from general anesthesia in an animal study conducted at Massachusetts General Hospital.

22 Sep 2011

EpiCept announces FDA's feedback on Ceplene clinical development for AML

EpiCept Corporation today announced that at a recent meeting with the U.S. Food and Drug Administration (FDA) the Company was provided more definitive guidance regarding the clinical development of Ceplene, the Company's lead product administered with interleukin-2 (IL-2) for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first complete remission.

12 Sep 2011

ICU patients less likely to renew prescriptions for chronic diseases after discharge

Patients often do not renew prescriptions for their chronic diseases after they are released from hospital.

25 Aug 2011

Health Canada accepts Sunovion Pharmaceuticals Canada's lurasidone NDS for review

Sunovion Pharmaceuticals Canada Inc., formerly Sepracor Pharmaceuticals, Inc., today announced that the New Drug Submission (NDS) for Lurasidone HCl, for the treatment of adult patients with schizophrenia has been accepted for review by Health Canada. The NDS was submitted to Health Canada in June 2011 and will receive a standard review.

24 Aug 2011

Study: IL-2 monotherapy not effective as maintenance therapy for acute myeloid leukemia

EpiCept Corporation announced today the publication of a new meta-analysis which concluded that interleukin-2 (IL-2) monotherapy is not effective as a maintenance therapy for acute myeloid leukemia (AML) patients in first complete remission. These results were published in the July 7, 2011 edition of Blood, a leading scientific journal in hematology.

18 Jul 2011

FDA responds to EpiCept Ceplene SPA

EpiCept Corporation today announced that it has received initial written responses from the U.S. Food and Drug Administration regarding the Company's application for a Special Protocol Assessment (SPA) of the Ceplene (histamine dihydrochloride) Phase III protocol.

27 Jun 2011

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.

24 Jun 2011